Hutchison China Meditech Limited Notice of Results (7080N)
February 03 2021 - 1:00AM
UK Regulatory
TIDMHCM
RNS Number : 7080N
Hutchison China Meditech Limited
03 February 2021
Chi-Med to Announce 2020 Final Results
Hong Kong, Shanghai, & Florham Park, NJ: Wednesday, February
3, 2021: Hutchison China MediTech Limited (!--Chi-Med!..)
(Nasdaq/AIM: HCM) will be announcing its final results for the year
ended December 31, 2020 on Thursday, March 4 , 2021 at 12:00 noon
Greenwich Mean Time (GMT) / 8:00 pm Hong Kong Time (HKT) / 7:00 am
Eastern Standard Time (EST).
Analysts and investors are invited to join a conference call and
audio webcast presentation with Q&A, conducted by Chi-Med
management.
The conference call and audio webcast will take place at 1:00 pm
GMT / 9:00 pm HKT / 8 :00 am EST on Thursday, March 4, 2021 and
will be webcast live via the company website at
www.chi-med.com/investors/event-information/ . The presentation
will be available for downloading before the conference call
begins. Details of the conference call dial-in will be provided in
the financial results announcement and on the company website. A
replay will also be available on the website shortly after the
event.
About Chi-Med
Chi-Med (Nasdaq/AIM: HCM) is an innovative, commercial-stage,
biopharmaceutical company committed, over the past twenty years, to
the discovery and global development of targeted therapies and
immunotherapies for the treatment of cancer and immunological
diseases. It has a portfolio of nine cancer drug candidates
currently in clinical studies around the world and extensive
commercial infrastructure in its home market of China. For more
information, please visit: www.chi-med.com .
CONTACTS
Investor Enquiries
Mark Lee, Senior Vice President +852 2121 8200
Annie Cheng, Vice President +1 (973) 567 3786
Media Enquiries
Americas - Brad Miles, Solebury Trout +1 (917) 570 7340 (Mobile)
bmiles@troutgroup.com
Europe - Ben Atwell / Alex Shaw, FTI Consulting +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779
545 055 (Mobile)
Chi-Med@fticonsulting.com
Asia - Joseph Chi Lo / Zhou Yi, Brunswick +852 9850 5033 (Mobile), jlo@brunswickgroup.com / +852 97
83 6894 (Mobile), y zhou@brunswickgroup.com
Nominated Advisor
Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK)
Limited +44 (20) 7886 2500
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORDZGGZLZNGMZG
(END) Dow Jones Newswires
February 03, 2021 02:00 ET (07:00 GMT)
Hutchison China Meditech (LSE:0J7G)
Historical Stock Chart
From Mar 2024 to Apr 2024
Hutchison China Meditech (LSE:0J7G)
Historical Stock Chart
From Apr 2023 to Apr 2024